Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quisinostat Plus Fractionated Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-WT Glioblastomas
NCT06824662Phase 1Active, not recruiting
- Sponsor
- Ivy Brain Tumor Center
- Start
- Sep 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of quisinostat in glioblastoma (GBM) (2 arms), sponsored by Ivy Brain Tumor Center. Primary endpoints: Quisinostat Concentration in Gadolinium-Non-Enhancing Tumor Tissue and 6-Month Progression Free Survival Rate at 16 months. Started Sep 2025; status: active, not recruiting.
02
Drugs
quisinostat
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06824662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06824662.